Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_2

50%

Ph phase_3

25%

Ph phase_4

13%

Ph not_applicable

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

4(50.0%)

Phase 3Large-scale testing

2(25.0%)

Phase 4Post-market surveillance

1(12.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(5)

Detailed Status

Withdrawn3

Completed3

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 4

Trials by Phase

Phase 24 (50.0%)

Phase 32 (25.0%)

Phase 41 (12.5%)

N/A1 (12.5%)

Trials by Status

withdrawn338%

completed338%

terminated225%

Recent Activity

0 active trials

Showing 5 of 8

completedphase_2

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

NCT00056641

withdrawnnot_applicable

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

NCT01165645

withdrawnphase_2

A Study of Combination Therapies to Treat COVID-19 Infection

NCT04459702

terminatedphase_2

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

NCT02116660

completedphase_3

Evaluation of Low-dose Darunavir in a Switch Study

NCT02671383

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT00056641Phase 2

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Completed

NCT01165645Not Applicable

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Withdrawn

NCT04459702Phase 2

A Study of Combination Therapies to Treat COVID-19 Infection

Withdrawn

NCT02116660Phase 2

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Terminated

NCT02671383Phase 3

Evaluation of Low-dose Darunavir in a Switch Study

Completed

NCT00771498Phase 4

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin

Completed

NCT01095094Phase 2

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Terminated

NCT01255371Phase 3

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir